The Role of Hepatitis B Virus Biomarkers for Diagnosing the Progression of Disease
Clicks: 1
ID: 311581
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #215 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Hepatitis B virus (HBV) infection remains a global public health concern, with over 296 million chronic carriers worldwide and an estimated 820,000 deaths annually due to HBV-related complications such as cirrhosis and hepatocellular carcinoma (HCC) [1]. While serological markers like hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) have long been used in diagnosis and monitoring, emerging research has revealed the value of novel biomarkers in assessing disease progression, predicting treatment response, and guiding personalized care strategies.
| Reference Key |
shadbash2025hepatitis
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Piruz Shadbash, Alireza Namazi |
| Journal | Yemen Journal of Medicine |
| Year | 2025 |
| DOI |
10.63475/yjm.v4i2.0161
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.